Shattuck Labs, Inc. (STTK)

Shattuck Labs, Inc. has experienced stock fluctuations influenced by financial reports, DR3 program updates, and participation in investor conferences. Analyst ratings and price target adjustments have also played a role, with Wedbush raising its target to $11 in May 2026. The stock has shown significant volatility, with a 52-week range of $0.71 to $8.33, and as of late April 2026, the share price was $7.74.

As a clinical-stage biotechnology company, Shattuck Labs, Inc. does not have commercialized products subject to demand seasonality. The company focuses on advancing its pipeline through preclinical and clinical development.

Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing treatments for autoimmune, inflammatory, and immune-mediated diseases. The company specializes in protein engineering, creating TNF superfamily receptor agonist and antagonist therapeutics. Their lead product candidate, SL-325, is a DR3 blocking monoclonal antibody for inflammatory bowel disease, currently in Phase 1 clinical trials with Phase 2 planned for Q3 2026. Shattuck Labs is also developing SL-425 and preclinical DR3-based bispecific antibodies.

Shattuck Labs, Inc. is headquartered in Austin, Texas, and has R&D facilities in Durham, North Carolina. The company primarily serves the U.S. market but plans to expand geographically as its clinical programs progress.

Shattuck Labs, Inc. has a "Moderate Buy" consensus rating from analysts, indicating a positive outlook. However, its GF Score of 46/100 suggests below-average performance potential due to struggles in profitability, growth, and valuation metrics. The company's reputation is primarily tied to its clinical trial progress and financial reporting, with no specific negative events reported in the past year beyond the inherent risks of a clinical-stage biotech company.

Shattuck Labs (STTK) has a mix of institutional, retail, and insider ownership. Retail investors hold a significant portion, with some data indicating they own the "lion's share" at 32% or approximately 74.26% of the stock. Institutional investors hold approximately 8.86% to 12.00% of the company's stock, with some reports indicating up to 58.74%. Insiders own about 13.73% of the stock. Major institutional owners include Adage Capital Partners Gp, L.l.c., Orbimed Advisors Llc and Redmile Group, LLC.